The Claim
Trifarotene, a fourth-generation retinoid with high selectivity for RAR-γ, is associated with a significant reduction in acne scarring and favorable tolerability over a 24-week treatment period in patients with moderate facial and truncal acne.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Trifarotene, a prescription acne medication, is linked to a measurable decrease in acne scars and fewer side effects in patients with moderate acne on the face and torso after 24 weeks of use.
See the scientific wording
Trifarotene, a fourth-generation retinoid with high selectivity for RAR-γ, is associated with significant reduction in acne scarring and favorable tolerability over 24 weeks in patients with moderate facial and truncal acne, based on randomized controlled trials and case series.
Trifarotene binds to a skin-specific receptor called RAR-γ, which turns on genes that fix clogged pores, calm skin inflammation, and rebuild damaged collagen. This stops new acne from forming, reduces redness and swelling, and repairs scars by replacing broken-down tissue with organized collagen fibers.
What the research says
1 studyStudy: Topical Retinoids in Acne Vulgaris and Acne Scars—From Monotherapy to Combining Regimens
This study says that newer acne creams like trifarotene help reduce acne scars and don’t irritate the skin as much as older ones, especially on the face and back — which matches what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.